Answers are grounded in this paper and cite their sources.
The blood-brain barrier (BBB) is a formidable physical and enzymatic barrier that tightly controls the passage of molecules from the blood to the brain. In fact, less than 2 % of all potential neurotherapeutics are able to cross it. Here, by applying the retro-enantio approach to a peptide that targets the transferrin receptor, a full protease-resistant peptide with the capacity to act as a BBB shuttle was obtained and thus enabled the transport of a variety of cargos into the central nervous system.
No takes yet. Share an insight, caveat, or question.
Prades et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: